Literature DB >> 21909794

[Precancerous lesions of the uterine cervix: morphology and molecular pathology].

L-C Horn1, K Klostermann.   

Abstract

HPV-induced alterations of the uterine cervix are frequently biopsied because of suspicious findings on a Pap smear and/or colposcopy. Precancerous lesions occur at the so called transformation zone. For those representing squamous differentiation, the traditional three-tier grading system in CIN 1 to 3 is used. CIN 1 and CIN 2 represent (spontaneous) regression in 60-90% and 50%, respectively. In CIN 3 lesions progression is seen in 20-50%. For appropriate grading, improvement of inter- and intraobserver correlation as well as the exclusion of non-precancerous lesions, p16 immunohistochemistry might be helpful. The terms endocervical glandular dysplasia and low-grade glandular intraepithelial neoplasia have been suggested for glandular lesions less than adenocarcinoma in situ (AIS). Until now reproducible histological criteria have not been established. Additional studies using HPV analysis, p16 and Ki-67 immunohistochemistry have not been proved for these lesions. In accordance with international consensus meetings, these diagnostic terms are not recommended for use in practice. AIS, characterised by the replacement of glandular epithelium by cytologically malignant cells, has been established as the precancerous lesion of the endocervix. AIS is much less common than CIN 3 with a reported range of 1:50-100. But, AIS is found in association with CIN 3 with 25-75%. The differential diagnosis between AIS and non-neoplastic glandular lesion may be aided by immunohistochemistry (e.g. p16, Ki-67, bcl-2, vimentin). All specimens obtained after the clinical diagnosis of cervical precancerous lesions should be examined using step sectioning to rule out microinvasive growth. Important information for clinicians includes the quality of the specimen (cautery artefacts, transformation zone enclosed within the probe), exact grading of CIN lesions, identification of other lesions responsible for suspicious findings of a Pap smear or at colposcopy, and in the case of conisation the distance of the lesion from the resection margins (endo- and ectocervical and circumferential margin).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21909794     DOI: 10.1007/s00292-011-1517-0

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  100 in total

1.  Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix.

Authors:  T R Denehy; C A Gregori; J L Breen
Journal:  Obstet Gynecol       Date:  1997-07       Impact factor: 7.661

2.  Superficial (early) endocervical adenocarcinoma in situ: a study of 12 cases and comparison to conventional AIS.

Authors:  Agnieszka Witkiewicz; Kenneth R Lee; Gilbert Brodsky; Aida Cviko; Joshua Brodsky; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2005-12       Impact factor: 6.394

3.  Endocervical intraepithelial glandular atypia (dysplasia): a histopathologic, human papillomavirus, and MIB-1 analysis of 25 cases.

Authors:  K R Lee; D Sun; C P Crum
Journal:  Hum Pathol       Date:  2000-06       Impact factor: 3.466

Review 4.  Cervical intraepithelial neoplasia.

Authors:  R M Richart
Journal:  Pathol Annu       Date:  1973

5.  The histologic diagnosis of adenocarcinoma in situ and related lesions of the cervix uteri. Adenocarcinoma in situ.

Authors:  R C Jaworski; N F Pacey; M L Greenberg; R A Osborn
Journal:  Cancer       Date:  1988-03-15       Impact factor: 6.860

6.  Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.

Authors:  W G McCluggage; R Shah; L E Connolly; H A McBride
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

7.  The topography and invasive potential of cervical adenocarcinoma in situ, with and without associated squamous dysplasia.

Authors:  T J Colgan; G M Lickrish
Journal:  Gynecol Oncol       Date:  1990-02       Impact factor: 5.482

8.  Squamous dysplasia of the uterine cervix: tissue sampling-related diagnostic considerations in 600 consecutive biopsies.

Authors:  Oluwole Fadare; Rosemarie Rodriguez
Journal:  Int J Gynecol Pathol       Date:  2007-10       Impact factor: 2.762

9.  Coexistence of cervical intraepithelial neoplasia with primary adenocarcinoma of the endocervix.

Authors:  R C Maier; H J Norris
Journal:  Obstet Gynecol       Date:  1980-09       Impact factor: 7.661

10.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Authors:  Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

View more
  4 in total

1.  [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology].

Authors:  L-C Horn; M W Beckmann; M Follmann; M C Koch; P Mallmann; S Marnitz; D Schmidt
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

2.  Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis.

Authors:  F Wang; X Liu; P Yang; L Guo; C Liu; H Li; S Long; Y Shen; H Wan
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

3.  SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma.

Authors:  Anton N H Hopman; Jobran M Moshi; Klaas J Hoogduin; Monique Ummelen; Mieke E R Henfling; Manon van Engeland; Kim A D Wouters; Hans Stoop; Leendert H J Looijenga; Frans C S Ramaekers
Journal:  Histopathology       Date:  2019-12-01       Impact factor: 5.087

Review 4.  Infection by High-Risk Human Papillomaviruses, Epithelial-to-Mesenchymal Transition and Squamous Pre-Malignant or Malignant Lesions of the Uterine Cervix: A Series of Chained Events?

Authors:  Giovanni Barillari; Roberto Bei; Vittorio Manzari; Andrea Modesti
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.